1-20 of 46 results for subject:Blood
Librarians' tools
- Search time
- 0.231 seconds
- Solr query time
- 0.007 seconds
- Search query
- subject:Blood
- We searched for
- subject_t:Blood OR subject_t:"Contaminated blood" OR subject_t:"Infected blood" OR subject_t:Plasma OR subject_ses:90356
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 May to Question 51941 on Paraneoplastic Encephalomyelitis: Diagnosis, whether the NHS routinely sends blood samples to the US for analysis when testing for Paraneoplastic Encephalomyelitis.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 May to Question 51941 on Paraneoplastic Encephalomyelitis: Diagnosis, whether the NHS routinely sends blood samples to the US for analysis when testing for Paraneoplastic Encephalomyelitis.
There are a number of laboratories in England which provide blood testing for paraneoplastic encephalomyelitis, although the Department has not made a specific formal estimate of how many there are. Several National Health Service laboratories across the United Kingdom also offer diagnostic testing for paraneoplastic antibodies. In England, these laboratories include the University College London Queen Square Institute of Neurology, and the Oxford University Hospitals NHS Foundation Trust.
The NHS in England does not routinely send blood samples to the United States for analysis when testing for paraneoplastic encephalomyelitis. There are specialised laboratories within the UK which the NHS in England uses to conduct these tests.
Lords motion to consider. Agreed to on question.
Lords motion to consider. Agreed to on question.
My Lords, in thanking the Minister for introducing these statutory instruments, I am conscious of two things. First, they are procedurally necessary because of the decision to leave the European Union, but inter alia, honour a commitment not to use such transitional arrangements to dilute our commitment to uphold the...
My Lords, in thanking the Minister for introducing these statutory instruments, I am conscious of two things. First, they are procedurally necessary because of the decision to leave the European Union, but inter alia, honour a commitment not to use such transitional arrangements to dilute our commitment to uphold the...
My Lords, I thank the Minister for introducing these regulations. Indeed, I remember taking part in that debate in January 2019—I am looking at the noble Baroness, Lady Thornton, and clearly she does, too. Although much time has passed, little has changed. We are still facing a situation in which...
My Lords, I thank the Minister for introducing these regulations. Indeed, I remember taking part in that debate in January 2019—I am looking at the noble Baroness, Lady Thornton, and clearly she does, too. Although much time has passed, little has changed. We are still facing a situation in which...
Like the noble Baroness, Lady Barker, and others in this Room, I have been involved in the legislation that is the subject of these regulations for, in my case, 20-odd years. I thank the Minister for his explanation of these regulations. If he looks back in the record to last...
Like the noble Baroness, Lady Barker, and others in this Room, I have been involved in the legislation that is the subject of these regulations for, in my case, 20-odd years. I thank the Minister for his explanation of these regulations. If he looks back in the record to last...
My Lords, I start by saying a profound thank you for a lively, insightful and patient debate, because I recognise that these issues have been visited before—and the debate only improves in the retelling. I shall try to trot through a number of points in quick order, because the debate...
My Lords, I start by saying a profound thank you for a lively, insightful and patient debate, because I recognise that these issues have been visited before—and the debate only improves in the retelling. I shall try to trot through a number of points in quick order, because the debate...
My Lords, I am likewise very grateful to my noble friend the Minister for his very clear explanation of the purpose of these regulations. I wish to speak only to the first set, relating to blood safety and quality.
As the Minister quite rightly explained, the purpose of the regulations is...
My Lords, I am likewise very grateful to my noble friend the Minister for his very clear explanation of the purpose of these regulations. I wish to speak only to the first set, relating to blood safety and quality.
As the Minister quite rightly explained, the purpose of the regulations is...
I thank my noble friend Lord Bethell for setting out these regulations so clearly. I strongly support all four sets of regulations; as he has said, they are vital to honour the withdrawal agreement. Indeed, that withdrawal agreement is at the base of the regulations we are considering. They essentially...
I thank my noble friend Lord Bethell for setting out these regulations so clearly. I strongly support all four sets of regulations; as he has said, they are vital to honour the withdrawal agreement. Indeed, that withdrawal agreement is at the base of the regulations we are considering. They essentially...
My Lords, I intend to focus my remarks on the human tissue and organ transplant regulations and, in particular, on the issues of timeliness and trust.
I have a particular interest in both of these issues. Back in 1995, I gave my consent in Brussels for organs from my deceased husband...
My Lords, I intend to focus my remarks on the human tissue and organ transplant regulations and, in particular, on the issues of timeliness and trust.
I have a particular interest in both of these issues. Back in 1995, I gave my consent in Brussels for organs from my deceased husband...
My Lords, these regulations are critical in giving effect to the Ireland/Northern Ireland protocol for the safety and quality of blood, organs, tissues and cells, including reproductive cells.
I will give a brief moment of context. In January, the European Union (Withdrawal Agreement) Act 2020 was agreed by this House. It...
My Lords, these regulations are critical in giving effect to the Ireland/Northern Ireland protocol for the safety and quality of blood, organs, tissues and cells, including reproductive cells.
I will give a brief moment of context. In January, the European Union (Withdrawal Agreement) Act 2020 was agreed by this House. It...
My Lords, I thank the Minister for introducing and explaining so carefully the statutory instruments. Clearly, as he said, they are very important. The key statement he made, which is repeated in paragraph 7.7 of the Explanatory Memorandum, is:
“Neither the 2019 SIs, nor the 2020 SIs make changes to the...
My Lords, I thank the Minister for introducing and explaining so carefully the statutory instruments. Clearly, as he said, they are very important. The key statement he made, which is repeated in paragraph 7.7 of the Explanatory Memorandum, is:
“Neither the 2019 SIs, nor the 2020 SIs make changes to the...
I too thank the Minister for presenting the statutory instruments. I will speak in particular to the blood safety and quality regulations. These are clearly very important and, as we get closer to the date by which a deal was meant to have been arrived at and there is not...
I too thank the Minister for presenting the statutory instruments. I will speak in particular to the blood safety and quality regulations. These are clearly very important and, as we get closer to the date by which a deal was meant to have been arrived at and there is not...
On a point of order, Mr Deputy Speaker. In response to my question this morning about compensation for the victims of the contaminated blood scandal, the Minister for the Cabinet Office and Paymaster General suggested that the Government were waiting for
“the determination of legal liability, to which the inquiry’s deliberations...
On a point of order, Mr Deputy Speaker. In response to my question this morning about compensation for the victims of the contaminated blood scandal, the Minister for the Cabinet Office and Paymaster General suggested that the Government were waiting for
“the determination of legal liability, to which the inquiry’s deliberations...
To ask the Secretary of State for Health and Social Care, whether the UK Government has accepted responsibility for the contaiminated blood products that were imported from the US during the 1970s and 1980s that caused some people in the UK to be infected with both HIV and Hepatitis.
To ask the Secretary of State for Health and Social Care, whether the UK Government has accepted responsibility for the contaiminated blood products that were imported from the US during the 1970s and 1980s that caused some people in the UK to be infected with both HIV and Hepatitis.
In July 2017 the Prime Minister announced a full public inquiry, under the Inquiries Act 2005, to conduct an independent review of all the events surrounding the tragedy of infection with blood products.
Following a consultation, the Inquiry’s wide ranging, and United Kingdom-wide terms of reference were presented to Parliament by the Chancellor of the Duchy of Lancaster (Rt. hon David Lidington MP), and published in July 2018.
Those terms of reference include to “…identify…any individual responsibilities, as well as organisational and systemic failures.”
Further information is available on the Inquiry’s website at the following link:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to find those responsible for the blood products that were imported from the US during the 1970s and 1980s which were contaminated and consequently caused people in the UK to be infected with...
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to find those responsible for the blood products that were imported from the US during the 1970s and 1980s which were contaminated and consequently caused people in the UK to be infected with...
In July 2017 the Prime Minister announced the creation of a full public inquiry, under the Inquiries Act 2005, to conduct an independent review of all the events surrounding the tragedy of infection with blood products.
Following a consultation, the Inquiry’s wide ranging, and United Kingdom-wide terms of reference were presented to Parliament by the Chancellor of the Duchy of Lancaster (Rt. hon David Lidington MP), and published in July 2018.
Chaired by Sir Brian Langstaff, the Inquiry is currently gathering evidence and is due to hear testimony from those affected by the events, as well as those responsible from the Government, the National Health Service and other organisations.
Further information is available on the Inquiry’s website at the following link:
To ask Her Majesty's Government how many NHS patients (1) are receiving, or (2) have in the last year received, blood plasma from compensated US donors.
To ask Her Majesty's Government how many NHS patients (1) are receiving, or (2) have in the last year received, blood plasma from compensated US donors.
Blood plasma supplied by NHS Blood and Transplant for transfusion to hospitals in England is either imported from Austria or comes from United Kingdom donors. Both sources are public, not privately sourced.
Blood plasma derived medicinal products are subject to medicinal regulation to assure their safety. Data are not held on the number of National Health Service patients receiving blood plasma medicinal products which may have been derived from United States donors.
The companies that supply plasma derived products to hospitals in England via NHS England’s Commercial Medicines Unit (CMU) frameworks are:
- CSL Behring;
- Grifols;
- Octapharma;
- BPL (Bio Products Laboratory);
- LFB Biomedicaments;
- Baxalta (now part of Shire); and
- Shire Pharmaceuticals.
Information is not held on supply of plasma derived medicinal products to NHS trusts outside of a CMU framework agreement.
There are a number of measures in place to ensure the safety and supply of plasma and medicinal products for patients.
All companies wishing to supply plasma derived medicinal products to hospitals in the UK have to be licensed by the Medicines and Healthcare products Regulatory Agency (MHRA). There are a series of stringent safety measures in place to prevent infections resulting from the use of medicinal products prepared from human blood or plasma, including selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. These measures are described in detail in the European Medicines Agency’s Guideline on plasma-derived medicinal products. A copy is attached.
The Department works closely with the MHRA, the pharmaceutical industry, NHS England and others to manage risks to the supply chain of blood plasma products to NHS patients.
My honourable friend the Parliamentary Under-Secretary of State for Defence (Derek Twigg) has made the following Written Ministerial Statement. As the Secretary of State for Defence informed the House on 10 January, a small number of UK service personnel who deployed to Iraq and Afghanistan in recent years have received...
My honourable friend the Parliamentary Under-Secretary of State for Defence (Derek Twigg) has made the following Written Ministerial Statement. As the Secretary of State for Defence informed the House on 10 January, a small number of UK service personnel who deployed to Iraq and Afghanistan in recent years have received...
As the Secretary of State for Defence informed the House on 10 January, a small number of UK service personnel who deployed to Iraq and Afghanistan in recent years have received life-saving emergency transfusions of US blood. We had identified from US and UK records that 18 of these UK...
As the Secretary of State for Defence informed the House on 10 January, a small number of UK service personnel who deployed to Iraq and Afghanistan in recent years have received life-saving emergency transfusions of US blood. We had identified from US and UK records that 18 of these UK...
(2) what advice her Department received between 1977 and 1989 from the World Health Organisation on the safety of imported blood from the US; and if she will make a statement.
(2) what advice her Department received between 1977 and 1989 from the World Health Organisation on the safety of imported blood from the US; and if she will make a statement.